Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

References 56

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.
    Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides · 2013

    No notice
16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.
    Cancer classification using the Immunoscore: a worldwide task force · 2012

    No notice
37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 55

• Current and future immunotherapeutic approaches in pancreatic cancer treatment · 2024
  No notice
• Cold and hot tumors: from molecular mechanisms to targeted therapy · 2024
  No notice
• Mitochondrial DNA-triggered innate immune response: mechanisms and diseases · 2023
  No notice
• STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma · 2023
  No notice
• Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity · 2023
  No notice
• Dendritic cell subsets in cancer immunity and tumor antigen sensing · 2023
  No notice
• STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer · 2022
  No notice
• STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity · 2022
  No notice
• Clathrin-associated AP-1 controls termination of STING signalling · 2022
  No notice
• Type I interferon-mediated tumor immunity and its role in immunotherapy · 2022
  No notice
• Combination strategies with PD-1/PD-L1 blockade: current advances and future directions · 2022
  No notice
• A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses · 2022
  No notice
• The cGAS/STING Pathway: A Novel Target for Cancer Therapy · 2022
  No notice
• Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy · 2022
  No notice
• Manganese salts function as potent adjuvants · 2021
  No notice
• A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection · 2021
  No notice
• ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance · 2021
  No notice
• STING suppresses bone cancer pain via immune and neuronal modulation · 2021
  No notice
• The cGAS-STING Pathway: A Promising Immunotherapy Target · 2021
  No notice
• Cancer Vaccines, Adjuvants, and Delivery Systems · 2021
  No notice

and 35 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.